618 results about "Clostridiales" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The invention relates to the use of a composition comprising n Streptococcus pneumoniae polysaccharides conjugated to the tetanus toxoid and p Streptococcus pneumoniae polysaccharides conjugated to the diphtheria toxoid, for manufacturing a vaccine which protects against Clostridium tetani and / or Corynebacterium diphtheriae infections in which: (1) n and p are other than 1, with p being, however, <=15, (2) 2<=n+p<=38, (3) the total amount of conjugated toxoid present in one vaccine dose is sufficient to induce protection against Clostridium tetani and / or Corynebacterium diphtheriae infections.

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.

Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and / or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

The present invention provides one kind of feed level microbe additive and its preparation and application. The microbe additive includes mainly probiotics part and nutritious liquid part. The probiotics part contains acidophilic lactobacillus, fecal enterococcin and butynic clostridium; and the nutritious liquid part contains acetic acid, propanoic acid and butyric acid. The feed level microbe additive is taken by chickling in 24 hr after hatching, and this can reduce the use amount of antiseptic medicine obviously, raise daily weight gain, lower the feed / meat ratio and raise economic utility obviously. In addition, it has simple preparation and low cost.

The invention discloses a biomarker capable of detecting diseases. The biomarker at least comprises one of the following microbes or the combination of the following microbes: Akkermansia muciniphila, Bacteroides fragilis, Clostridium bolteae, Clostridium hathewayi, Clostridium sp.HGF2, Clostridium symbiosum, Eubacterium limosum, Lactobacillus fermentum, Lactobacillus salivarius, Ruminococcus torques, Streptococcus anginosus, Streptococcus infantis, Bacteroides stercoris, Bacteroides uniformis, Bilophila wadsworthia and Clostridiales sp.SS3 / 4. The invention further discloses an application of the biomarker for determining inflammatory bowel diseases. The invention also discloses a method, a system and a kit for detecting the biomarker in a tested object. According to the invention, through the research on intestinal flora, and through the high-throughput genome sequencing, the biomarker with high relativity with the inflammatory bowel diseases is screened out, and then the biomarker is utilized for accurately and efficiently detecting and diagnosing the inflammatory bowel diseases, and further used for monitoring the treatment effect for the disease.

The invention discloses preparation and application of Clostridium butyricum and a live Clostridium butyricum preparation; Clostridium butyricum LXKJ-1 is collected in China Center for Type Culture Collection on 24 March, 2016 under CCTCC NO: M201613. A seed medium, fermentation medium formulation, culture conditions for Clostridium butyricum and a production of a preparation of live Clostridium butyricum are also disclosed. The Clostridium butyricum provided herein is tolerant to acids, bases and high temperature, is highly capable of producing butyric acid, can inhibit animal pathogens, such as Escherichia coli, Salmonella, Shigella, Staphylococcus aureus, Listeria monocytogenes, and Clostridium perfringens, and can prevent diarrhea in livestock and poultry due to Escherichia coli, Salmonella and Clostridium perfringens, improving intestinal flora balance, promoting the growth of livestock and poultry, relieving constipation in sows, improving egg weight for layers, improving eggshell quality for layers, and decreasing egg-feed ratio.

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

The invention relates to a clear liquid fermentation medium for clostridium butyricum. The clear liquid fermentation medium, the pH value of which is 7-8, is made from glucose, tryptone, a yeast extract powder, ammonium sulfate, sodium bicarbonate, a maize liquid powder and the like. The clear liquid fermentation medium for clostridium butyricum contains metal salts for promoting the growth of gemma, wherein the metal salts are manganese sulfate, magnesium sulfate and ferrous sulphate. The enrichment medium of the clear liquid fermentation medium for clostridium butyricum contains yeast extract, beef extract, tryptone, glucose, soluble starch, sodium chloride, sodium acetate trihydrate, cysteine hydrochloride, methylene blue at the concentration of 0.5% and distilled water; and the pH is adjusted to 7.1. A fermentation culture method of the clear liquid fermentation medium for clostridium butyricum comprises the following steps of: glycerin tube refrigerated strain activation, heating and optimization, Erlenmeyer flask first-order seed culture, liquid fermentation and spray drying. The production of clostridium butyricum has advantages of simple operation, high amount of zymocyte, high gemma yield, simple post-treatment, less impurities in a bacterial powder sample and high amount of effective live bacteria, and saves cost at large.

The invention discloses a method for the comprehensive utilization of lignocellulosic biomasses, which comprise the following steps: (1) crushing a raw lignocellulose material and adding water so as to form mixed liquid, adding alkaline for adjustment, adding sulfite, and cooking the obtained object so as to obtain a mixture; (2) carrying out solid-liquid separation on the mixture obtained in the step (1), washing and cooling an obtained solid, mixing liquid obtained by washing with liquid obtained by solid-liquid separation, cyclically applying the obtained mixture to the step (1), and when the dry matter content of the liquid reaches a certain value, drying the liquid so as to obtain sulfonated lignin; (3) adjusting the pH value of the solid washed in the step (2), adding cellulase liquid, and carrying out highly enriched material saccharification; (4) adding a yeast into saccharification liquid obtained in the steps (3) to ferment, and treating the fermented mixture so as to obtain anhydrous ethanol; and (5) feeding clostridium beijerinckii into the waste fermentation liquor obtained in the step (4) to ferment, and then distilling the obtained object so as to produce ethanol, acetone and butanol. According to the invention, the efficient utilization of main ingredients such as lignin, cellulose and hemicellulose in lignocellulose biomasses is realized.

The present invention is directed to a method for detecting the presence of clostridial neurotoxins in a sample by mixing a sample with a peptide that can serve as a substrate for proteolytic activity of a clostridial neurotoxin; and measuring for proteolytic activity of a clostridial neurotoxin by a mass spectroscopy technique. In one embodiment, the peptide can have an affinity tag attached at two or more sites.

The invention discloses a method for improving the sugar utilization rate of clostridium acetobutylicum in fermentation of mixed sugar. The method comprises the following steps of: performing gene engineering modification on clostridium acetobutylicum, so that compared with wild type clostridium acetobutylicum, the clostridium acetobutylicum has the advantages that expression of g1cG gene can be inhibited, and the expression and activity of xylose transportprotein, xylose isomerase, and / or xylulokinase can be improved; and applying the obtained clostridium acetobutylicum which is subjected to gene engineering to fermentation of sugar. By the method, more xylose and arabinose can be used by clostridium acetobutylicum in the fermentation of the mixed sugar, a solvent product with high concentration can be produced, and the product yield can be improved; and the method has excellent industrial application prospect.

The invention discloses a method for breeding black soldier fly larvae. The method includes steps of S1, uniformly mixing livestock and poultry feces which is fermented at the high temperatures, wheatbran, humus, brown sugar and clostridium butyricum with one another according to a mass ratio to prepare black soldier fly breeding bait; S2, breeding the larvae, to be more specific, inoculating 1-2g of newly hatched black soldier fly larvae in every 1 kg of black soldier fly breeding bait, carrying out culture on the newly hatched black soldier fly larvae at the temperatures of 25-35 DEG C for6-8 days and carrying out screening to obtain the mature black soldier fly larvae. The mass ratio of the livestock and poultry feces to the wheat bran to the humus to the brown sugar to the clostridium butyricum is 900-1000:40-60:20-40:4-5:1-3. The method has the advantages that growth and ingestion of the black soldier fly larvae can be promoted by the aid of the method, the livestock and poultry feces consumption speeds can be increased, the culture cycle of the black soldier fly larvae can be shortened, the protein content of black soldier fly can be increased, the black soldier fly larvaeobtained by the aid of the method can be used as a raw material for active feed or protein-source feed, and the method has a great application prospect.

The invention relates to hydroxysteroid dehydrogenase and particularly relates to a clostridium sardiniense 7alpha-hydroxysteroid dehydrogenase mutant T145S. The amino acid sequence of the clostridium sardiniense 7alpha-hydroxysteroid dehydrogenase mutant T145S is shown by SEQ ID No:2 and obtained by changing the 145th-site amino acid of the 7alpha-hydroxysteroid dehydrogenase with an amino acid sequence of SEQ ID No:1 from Thr into Ser. The mutant is 4.85 times of a wild type in the catalysis efficiency against the substrates TCDCA and NADP<+> and has a huge application potential in a biotransformation process of CDCA / TCDCA for obtaining UDCA / TUDCA.

The invention discloses microbial fermentation feed. The microbial fermentation feed is prepared from, by weight, 3-5 parts of a complex microbial agent, 680-730 parts of a fermentation raw material,275-325 parts of an energy raw material, 350-400 parts of water and 1-2 parts of brown sugar by mixed fermentation. The complex microbial agent is made by mixing of 5-6 of bacillus subtilis, enterococcus faecalis, plant lactobacillus, bacillus pumilus, clostridium butyricum, bacillus megaterium, bacillus amyloliquefaciens or lactobacillus casei. By fermentation treatment of the fermentation raw material and the energy raw material with the complex fermentation strain, enzymolysis of coarse fibers in the fermentation raw material is realized, organic nitrogen and inorganic nitrogen, which can be hardly used by animals, in the fermentation raw material are converted into bacterial protein, and macromolecular carbohydrates, which cannot be absorbed by the animal, in the energy raw material are converted into absorbable low-molecule carbohydrates.

The invention discloses a bdellovibrio bacteriovorus bacterial strain eliminating aquatic product Gram-positive pathogenic bacterium and an application thereof. The invention separates to obtain bdellovibrio bacteriovorus BDS02 the length of flagellum of which is at least 1.8mu m. The bdellovibrio bacteriovorus with flagellum on the end is cambered single cell the size of which is 0.65*0.2 mu m when observed by an electron microscope. The two layer plating method is used for cultivating the bdellovibrio bacteriovorus bacterial strain at the temperature of 28 DEG C for four days to form transparent round negativecolony the diameter of which is 1-2mm. Before the microorganism preparation prepared by the bdellovibrio bacteriovorus BDS02 is eaten by aquatic products, common Gram-positive pathogenic bacteria comprising Mycobacterium tuberculosis, star-shaped nocardia asteroids, rhodococcus erythropolis, streptococcus faecalis, staphylococcus epidermidis, clostridium perfringens and corynebacterium glutamicum in the transportation process and cultivation process can be eliminated, which improves the safe factor of raw aquatic products for consumers, protects the health of the consumers and provides guarantee for greenly processing and producing the aquatic products.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

Antimicrobial compositions for oral delivery, and administration to the colon, distal ileum, or other portion of the gastrointestinal tract other than the stomach, of bacteriophage, phage proteins, antimicrobial peptides, or antimicrobial aptamers, are disclosed. In one embodiment, the active agent is capable of lysing the bacterial cell wall. In another embodiment, the active agent is capable of interacting with a receptor or enzyme in the bacteria. In some embodiments, the active agents selectively act on one or more harmful bacteria, such as Clostridium difficile, and either do not act, or act to a lesser extent, on helpful bacteria, such as bifidobacteria. When the agents are not delivered directly to the colon, they active agents ultimately enter the colon and affect the bacteria that are present in the colon. The compositions can include beads of pectin in the form of a cationic salt enclosing the active agent, or other types of drug delivery systems designed for targeted delivery to the desired portion of the gastrointestinal tract.

The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum. It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene / divinyl-benzene base and / or on base of in particular ceramic hydroxylapatite.

The invention discloses a rabbit triple inactivated vaccine, a preparation method and the application thereof; the rabbit triple inactivated vaccine is formed mainly by rabbit hemorrhagic disease virus liquid which is inactivated and detoxified, rabbit pasteurella multocida liquid and rapid A type clostridium perfringens liquid which have 1:1:2 volume ratio; in the invention, by optimizing culture technology, concentration technology and immunizing dose and other measures, the rabbit triple inactivated vaccine which has good immunity effect and safety is obtained and can effectively control the rabbit hemorrhagic disease, the pasteurella multocida disease and the pasteurella multocida disease (A type) and reduce vaccine injection times of farmers, so as to reduce the stress reaction of animals and improve the production performance. The clinical application proves that the immunization effect of the rabbit triple inactivated vaccine is ideal, each rabbit is vaccinated with 2ml and has immunity after 5-7 days, the immune period is at least 180 days, and the immune safety is good without toxic and side effect.

The invention discloses a clostridium beijerinckii strain CM 20 with high yield of butanol, wherein the classification name of the clostridium beijerinckii strain CM 20 is Clostridium beijerinckii, and the clostridium beijerinckii strain CM 20 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 17, 2014, and has the preservation number CGMCC No.9354. The clostridium beijerinckii strain CM 20 provided by the invention can be used for producing butanol with high yield through fermentation by utilizing lignocellulose enzymatic hydrolysate detoxified by calcium hydroxide, the total solvent yield can achieve 19g / l, the sugar utilization ratio is high, the yield of butanol is high, and the problems that the capacity of the strain and the raw materials are insufficient when the traditional biological fermentation method is adopted for producing butanol are solved.

The invention relates to a fermentation method and application of high-concentration clostridium butyricum. The fermentation method includes the following steps that S100, inoculated fermentation, wherein clostridium butyricum strain liquid with the volume fraction of 5-10% is inoculated to a clostridium butyricum fermentation culture medium and cultured at the temperature of 35-38 DEG C and pH of 6.0-6.5 for 10-20 hours; S200, fed-batch fermentation, wherein fed batch of a mixed carbon source is conducted, the fed-batch fermentation is conducted for 20-40 hours, and the mixed carbon source includes 60-100 g / L sugar and 100-140 g / L sodium acetate; S300, sporulating fermentation, wherein after fed-batch fermentation is completed, a compound liquid containing calcium, magnesium and manganese is added, the sporulating fermentation is conducted for 10-30 hours, and clostridium butyricum is sporulated. The fermentation method largely improves the concentration of clostridium butyricum thalli, promotes the synthesis of butyric acid as a metabolite and can also produce clostridium butyricum and butyric acid with the high performance-price ratio, the advantages of industrialization are further improved, benefits are increased, and the environmental-protection requirements are achieved and met.

The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.

A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.